CStone Pharmaceuticals Valuation Multiples

CStone Pharmaceuticals Overview

About CStone Pharmaceuticals

CStone Pharmaceuticals is engaged in developing and commercializing of immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment.

Founded

2015

HQ

Employees

230

Website

cstonepharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $48M

EBITDA: ($54M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

CStone Pharmaceuticals Financials

CStone Pharmaceuticals reported last 12-month revenue of $48M and negative EBITDA of ($54M).

In the same LTM period, CStone Pharmaceuticals generated $17M in gross profit, ($54M) in EBITDA losses, and had net loss of ($45M).

CStone Pharmaceuticals P&L

In the most recent fiscal year, CStone Pharmaceuticals reported revenue of $60M and EBITDA of ($4M).

CStone Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

CStone Pharmaceuticals Stock Performance

CStone Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.

CStone Pharmaceuticals' stock price is $1.29.

CStone Pharmaceuticals Valuation Multiples

CStone Pharmaceuticals trades at 37.4x EV/Revenue multiple, and (33.6x) EV/EBITDA.

CStone Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, CStone Pharmaceuticals has market cap of $2B and EV of $2B.

Equity research analysts estimate CStone Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

CStone Pharmaceuticals has a P/E ratio of (41.7x).

CStone Pharmaceuticals Margins & Growth Rates

CStone Pharmaceuticals' revenue in the last 12 month grew by 156%.

CStone Pharmaceuticals' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

CStone Pharmaceuticals' rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CStone Pharmaceuticals' rule of X is 148% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

CStone Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

CStone Pharmaceuticals M&A Activity

CStone Pharmaceuticals acquired XXX companies to date.

Last acquisition by CStone Pharmaceuticals was on XXXXXXXX, XXXXX. CStone Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

CStone Pharmaceuticals Investment Activity

CStone Pharmaceuticals invested in XXX companies to date.

CStone Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. CStone Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).